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ABSTRACT
Metastatic melanoma of the skin has a high mortality despite the recent 
introduction of targeted therapy and immunotherapy. Long non-coding RNAs 
(lncRNAs) are defined as transcripts of more than 200 nucleotides in length that lack 
protein-coding potential. There is growing evidence that lncRNAs play an important 
role in gene regulation, including oncogenesis. We present 13 lncRNA genes involved 
in the pathogenesis of cutaneous melanoma through a variety of pathways and 
molecular interactions.  Some of these lncRNAs are possible biomarkers or therapeutic 
targets for malignant melanoma.
NON-CODING RNA: FROM JUNK 
SEQUENCES TO REGULATORS OF 
DISEASE
Only 2% of the human genome sequence is 
translated into proteins.[1] Until recently, it was believed 
that only this small fraction of the genome contained 
relevant information. The remaining 98% of the human 
genome was referred to as useless ‘junk DNA’.[1-
3] Recent advances in RNA-sequencing technology 
demonstrated that about 70% of this DNA can be 
transcribed into non-coding RNA (ncRNA) transcripts.
[4] Unlike messenger RNAs, ncRNAs do not serve as a 
template for protein synthesis, but instead play a pivotal 
role in regulating protein-coding gene expression.[5] This 
mechanism seems more important in complex organisms, 
as suggested by the positive correlation between organism 
complexity and the proportion of the genome that is not 
coding for proteins.[6] There is increasing evidence that 
mutations and polymorphisms in the non-coding genome 
are associated with human disease.[7, 8] Small ncRNAs 
such as microRNAs (miRNAs, 18-24 nucleotides in 
length) are to be distinguished from long ncRNAs 
(lncRNAs, >200 nucleotides). MiRNAs are generally 
more sequence conserved across species and tissues and 
have been studied in more detail compared with the more 
recently discovered lncRNAs. While miRNAs negatively 
regulate gene expression, lncRNAs may induce or repress 
gene expression. As miRNAs have been studied for over 
a decade, medicines based on miRNAs are currently in 
clinical development whereas this is not yet the case for 
lncRNAs.[9, 10] Compared to miRNAs, the function of 
lncRNAs may be more specific in terms of species, tissue 
and tumor type. In addition, current research indicates that 
lncRNAs contribute to each of the six core hallmarks of 
cancer, as defined by Hanahan and Weinberg in 2000.[8, 
11, 12] LncRNAs may thus be suitable both as biomarkers 
and as therapeutic targets. 
THE FUNCTION OF LNCRNAS
The functional evaluation of lncRNAs often relies 
on suppressing the activity of lncRNA (knockdown) and 
observing the resulting molecular phenotypes. Targeted 
knockdown of lncRNAs can be achieved using three 
different techniques: antisense oligonucleotides (ASO), 
RNA interference (RNAi) technology and more recently, 
the clustered regularly interspaced short palindromic 
repeats (CRISPR)/CRISPR-associated (Cas) system or 
the Crispr/Cas system.[13-16] All of these knockdown 
techniques can potentially be used for therapeutic 
purposes. LncRNAs exert their function through 
interactions with other cellular molecules, including 
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chromatin, proteins and RNA.[8] LncRNAs can influence 
the transcription of genes as they bind and (re-)position 
transcription factors or proteins that help define the 
structure of chromatin.[17] 
LncRNAs can repress gene expression through 
recruitment of the polycomb repressive complex 2 
(PRC2) towards specific loci in the genome, resulting in 
tri-methylation of H3K27, marking transcriptionally silent 
chromatin. This mechanism was observed for HOTAIR, a 
lncRNA transcribed from the HOXC locus that interacts 
with PRC2.[18] Alternatively, lncRNAs can activate 
gene expression. This can occur through recruitment of 
the WDR5/MLL complex, resulting in tri-methylation 
of H3K4 [19] or through the recruitment of the Mediator 
complex, resulting in phosphorylation of H3S10 [20]. 
The lncRNA molecular functions include decoys or 
guides for transcription factors and chromatin modifiers; 
scaffolds for multi-protein complexes and sponges for 
miRNAs.[21] These functions are not mutually exclusive 
as several lncRNAs exhibit complex functions through 
the combination of multiple molecular mechanisms.
[17] Cellular localization plays an important role in 
defining or restricting the function of lncRNAs. Many 
lncRNAs regulate nuclear events (chromatin interactions, 
transcriptional regulation and RNA processing), while 
cytoplasmic lncRNAs modulate mRNA stability or 
translation and influence cellular signaling cascades.[22] 
Apart from a functional classification, lncRNAs are often 
categorized on the basis of their genomic location and 
orientation compared to protein-coding genes (eg, sense, 
antisense, intronic of intergenic).[21, 23, 24]
IDENTIFICATION OF LNCRNAS IN 
CUTANEOUS MELANOMA AND THEIR 
MOLECULAR INTERACTIONS
Malignant melanoma, a skin cancer arising from 
melanocytes, has an increasing incidence and a high 
mortality rate. While localized melanoma is effectively 
cured by surgical excision, the prognosis for metastatic 
melanoma remains poor despite recent therapeutic 
progress.[25] Oncogenic transformation of melanocytes 
to melanoma is the result of complex changes in multiple 
signaling pathways controlling cell cycle progression 
and apoptosis. A constitutive activation of the RAS/
ERK/MAPK signaling pathway is frequently driven by 
activating mutations in BRAF or NRAS.[26] Activating 
mutations in the BRAF oncogene are present in 50 to 60% 
of melanomas, 90% of which produce an active mutant 
BRAFV600E protein.[27-29] Recently developed BRAF 
inhibitors as well as immune checkpoint inhibitors can be 
highly effective in some patients leading to a tremendous 
survival gain in metastatic melanoma.[30, 31] However, a 
substantial proportion of patients either do not respond or 
develop therapy resistance.[32-35] 
Recent studies indicate that lncRNAs are involved in 
the pathogenesis of malignant melanoma. Here, we review 
the growing body of literature on lncRNAs in melanoma 
and their possible clinical relevance. We identified 
thirteen human lncRNAs implicated in the pathogenesis 
of melanoma, as summarized in Table 1. The lncRNAs 
reported to be involved in the pathogenesis of cutaneous 
melanoma exert their function through different pathways 
and they interact with different molecular targets. A 
possible classification based on the currently known 
molecular interactions is provided below. 
Regulation of apoptosis
Sprouty4-intronic transcript 1 (SPRY4-IT1 or 
SPRIGHTLY), a lncRNA derived from an intron of 
the SPRY4 gene, was the first lncRNA characterized in 
melanoma. Besides melanoma, SPRY4-IT1 has been 
reported to play an important role in esophageal squamous 
cell carcinoma,[36] prostate cancer,[37] glioma[38] and 
gastric cancer.[39] Mazar et al.[40] suggested that SPRY4-
IT1 inhibits apoptosis via binding to LPIN2, thus altering 
lipid metabolism by avoiding cellular lipotoxicity. It 
has also been suggested that SPRY4-IT1 plays a role in 
post-transcriptional gene silencing based on its predicted 
secondary RNA structure with specific regulatory 
motifs.[41, 42] Others have suggested that SPRY4-IT1 
manipulates the RAS/ERK pathway given its membership 
of the Sprouty family of RAS/ERK inhibitor proteins that 
prevent the formation of active GTP-RAS.[43] However, 
these hypotheses still need to be confirmed experimentally.
LncRNAs associated with BRAF mutation
In an attempt to define the impact of oncogenic 
BRAFV600E expression on the melanocyte transcriptome, 
Flockhart et al.[44] performed massively parallel RNA 
sequencing analysis on both normal melanocytes and 
two BRAFV600E-mutant human primary melanoma 
specimens and identified BRAF-activated non-coding 
RNA (BANCR). BANCR is overexpressed in BRAFV600E 
melanoma cells. RNAi-dependent knockdown of BANCR 
inhibited melanoma cell migration by upregulating 
the chemokine CXCL11, a regulator of cell migration.
[44] BANCR is also capable to promote melanoma 
proliferation by activating the ERK1/2 and JNK MAPK 
pathways both in vitro and in vivo in a mouse model.[45] 
More recently, upregulated BANCR expression has also 
been reported in retinoblastoma,[46] colorectal cancer 
[47] and gastric cancer.[48] In contrast, BANCR was 
downregulated in non small cell lung cancer (NSCLC).
[49]
Based on the human Expressed Sequence Tag (EST) 
data and The Cancer Genome Atlas (TCGA) data, RMEL3 
was identified as a lncRNA with a specific and increased 
expression in melanoma compared with normal tissues 
and melanocytes.[50, 51] A positive correlation between 
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Table 1: Long non-coding RNAs in malignant cutaneous melanoma
lncRNA expression in melanoma cells/tissue analyzed molecular interactions
putative or confirmed 
effect
potential clinical 
relevance references
SPRY4-IT1 upregulated
- human melanoma cell lines, normal 
melanocytes and keratinocytes
- 30 melanoma patient samples and normal 
skin samples
- plasma samples from 70 patients and 79 
healthy controls
binds to LPIN2
promotes melanoma 
cell proliferation, 
migration and 
invasion; inhibits 
apoptosis
prognosis (SPRY4-
IT1 plasma level 
independent negative 
prognostic factor)
[40, 41, 
91, 92]
BANCR upregulated
- melanocytes +/- BRAFV600E mutation 
- 2 BRAFV600E-mutant primary melanoma 
specimens
- 103 primary melanoma samples and 12 
melanocytic nevus samples  
- 5 human melanoma cell lines
interacts with 
chemokine CXCL11
promotes melanoma 
cell migration
- prognosis (positive 
correlation between 
BANCR expression 
and tumor stages, 
univariate survival 
analysis)
- therapeutic target 
[44, 45, 
97]activates the ERK1/2 
and JNK MAPK 
pathway
promotes melanoma 
cell proliferation
HOTAIR upregulated
- 3 primary melanoma samples and matched 
lymph node metastases
- 9 benign nevi samples, 7 primary melanoma 
samples pT1a, 30 pairs of primary melanoma 
samples pT3/4 with corresponding metastases 
and 32 visceral metastases
- serum samples of 34 patients 
- human metastatic melanoma cell line A375
- 63 melanoma samples and paired adjacent 
normal tissue
- in silico analysis of Gene Expression 
Omnibus data
interacts with PRC2
promotes melanoma 
cell migration and 
invasion. promotes 
degradation of 
extracellular matrix 
(metastatic potential)
- therapeutic target in 
metastatic melanoma
- prognosis (positive 
correlation between 
HOTAIR expression 
and tumor stages) 
[62, 70, 
72]}
MALAT1 upregulated
- human melanoma cell line A375
- 63 melanoma samples, paired adjacent 
normal tissue and lymph node metastases
- 3 primary melanoma samples and matched 
lymph node metastases
interacts with splicing 
factors
MALAT1 knockdown 
hampers the migration 
of melanoma cells
prognosis (MALAT-1 
as prognostic 
indicator of lymph 
node metastasis in 
melanoma)
[62, 67, 
70]
interacts with miR-183 
and ITGB1
promotes melanoma 
cell proliferation
UCA1 upregulated
- human melanoma cell lines (A375 and 
SK-MEL-2)
- 3 primary melanoma samples and matched 
lymph node metastases
- 19 metastatic melanoma tissue samples, 18 
primary melanoma samples and 20 benign 
nevi samples
binds miR-507
promotes melanoma 
cell proliferation, 
migration and invasion
- prognosis (UCA-1 as 
prognostic indicator of 
lymph node metastasis 
in melanoma)
- UCA1-miR-507-
FOXM1 as an 
epigenetic therapeutic 
target
[62, 63]
CASC15 upregulated 
- melanocyte cultures 
- 30 human melanoma cell lines
- human melanoma xenograft mouse model of 
brain metastasis
- 141 primary melanoma samples and 
metastatic tissue
unknown
promotes melanoma 
cell transition between 
proliferative and 
invasive states
prognosis (CASC15 
level is an independent 
predictor of disease 
recurrence in patients 
with stage III 
melanoma)
[84]
ANRIL upregulated 
- human cutaneous melanoma cell line A375 
and uveal melanoma cell line OM431
- 18 cutaneous, 10 uveal primary melanoma 
samples and 9 benign nevus/choroid/retina 
tissue samples
negatively regulates 
the expression of 
tumor suppressor 
proteins CDKN2A/2B
ANRIL knockdown 
hampers the migration 
of melanoma cells and 
reduces clonogenicity
- early diagnostic 
marker
- therapeutic target
[52] [88, 
89]
RMEL3 upregulated 
- Human Expressed Sequence Tag and The 
Cancer Genome Atlas data
- 20 human melanoma cell lines, including 
A375-SM 
- 19 nevi, 19 primary and 17 metastatic 
melanoma tissue samples
interferes with MAPK 
and PI3K signalling
RMEL3 knockdown 
decrease melanoma 
cell survival and 
proliferation
therapeutic target [50, 51]
SNHG5 upregulated 
- serum of 24 melanoma patients, 15 healthy 
subjects and 5 patients with spinocellular 
carcinoma
- 36 primary melanoma samples and 4 nevi 
samples
unknown unknown
- early diagnostic 
marker
- monitoring of 
recurrence
[90]
SLNCR1 upregulated 
- The Cancer Genome Atlas data 
- melanoma short-term cultures and fibroblast 
short-term cultures derived from the tumor
interacts with AR and 
BRN3A, resulting in 
the upregulation of 
MMP9
promotes melanoma 
cell invasion
- prognosis (high 
expression of SLNCR1 
was associated 
with shorter overall 
survival)
- therapeutic target 
[75]
SAMMSON upregulated 
- melanoma patient derived tumor xenograft 
mouse model 
- The Cancer Genome Atlas data
- 17 human melanoma cell lines
interacts with p32, 
a master regulator 
of mitochondrial 
homeostasis and 
metabolism
SAMMSON 
knockdown reduces 
clonogenicity
- diagnostic marker
- therapeutic target [58]
LLME23 upregulated human melanoma cell lines (YUSAC, A2058, YU-SIT1, SKmel28)
binds with PSF. 
Suppresses proto-
oncogene RAB23
LLME23-knockdown 
decreases colony 
forming ability of 
melanoma cells
therapeutic target [60]
GAS5 downregulated
- human melanoma cell lines (HaCaT, A375, 
SK-Mel-28, SK-Mel-110 and M21)
- tumor mouse model
possibly interacts with 
MMP2
inhibits the migration 
and invasion of 
melanoma cells
only preclinical 
research available [80, 93]
Oncotarget4www.impactjournals.com/oncotarget
RMEL3 expression and the presence of the BRAFV600E 
mutation was reported.[50] RMEL3 knockdown in 
melanoma cells of the A375-SM cell line resulted in the 
inactivation of the critical MAPK and PI3K signaling 
pathways.[51] BANCR and RMEL3 are two lncRNAs 
that seem to exert their effect through the MAPK pathway.
Regulation of cell proliferation
Antisense non-coding RNA in the INK4 locus 
(ANRIL) was discovered after sequence-tagged site 
reverse transcriptase polymerase chain reaction (RT-
PCR) based gene dose mapping of the entire INK4/
ARF locus in a family with melanoma and neural system 
tumors.[52, 53] ANRIL is transcribed as a lncRNA in 
the antisense orientation relative to the P15/CDKN2B/
INK4B-P16/CDKN2A/INK4A-P14/ARF cluster. The 
latter gene cluster encodes three tumor suppressor proteins 
and its transcription is an important barrier for tumor 
growth. CDKN2A mutations have been implicated in 
approximately 20-40% of familial melanomas.[54] ANRIL 
is thus believed to participate directly in epigenetic 
transcriptional repression.[53, 55] Apart from melanoma, 
ANRIL expression was upregulated in various other 
malignancies, such as colorectal cancer [56] and NSCLC.
[57]
Recently, Survival Associated Mitochondrial 
Melanoma Specific Oncogenic RNA (SAMMSON) was 
identified by Leucci et al.[58, 59] as a novel melanoma-
specific lncRNA that interferes with mitochondrial 
metabolism. Mechanistic studies indicated that 
SAMMSON interacts with P32, a master regulator of 
mitochondrial metabolism, to increase its mitochondrial 
targeting and promote oxidative phosphorylation.[58]
LLME23 seems to be involved in the colony 
forming ability of melanoma cells. LLME23 binds 
polypyrimidine tract-binding protein-associated splicing 
factor (PSF, also known as SFPQ).[60] PSF can exert a 
tumor-suppressor function by binding to the promoter of 
the proto-oncogene RAB23 that encodes a RAS-related 
small GTPase.[60] 
Urothelial carcinoma associated 1 (UCA1) was 
originally detected in bladder transitional cell carcinoma 
where it is believed to promote invasion and cancer 
progression.[61] In melanoma, UCA1 was found to be 
upregulated in both primary and metastatic melanoma 
samples.[62, 63] UCA1 is believed to exert its oncogenic 
functions by acting as a miRNA sponge for miR-507. As 
a result, FOXM1, a target of miR-507, is downregulated 
upon UCA1 depletion in melanoma cell lines, resulting in 
the inhibition of cell proliferation.[63]
Metastasis-associated lung adenocarcinoma 
transcript 1 (MALAT1), also known as nuclear-enriched 
transcript 2 (NEAT2), was discovered as a prognostic 
marker for lung cancer metastasis.[64] Since its 
discovery in 2003, MALAT1 has been one of the most 
studied lncRNAs so far and is overexpressed in multiple 
carcinomas.[65, 66] In melanoma, MALAT1 may 
promote cell proliferation and invasion through a complex 
interaction with miR-183 and integrin β1 (ITGB1).[67]
Regulation of metastasis
HOX antisense intergenic RNA (HOTAIR) is 
transcribed from the HOXC cluster and recruits PRC2 
to specific target genes, leading to H3K27 trimethylation 
and epigenetic silencing of metastatic suppressor genes.
[18, 68, 69] HOTAIR deregulation is associated with 
prometastatic activity in melanoma [70-72], but also in 
breast cancer, [69] cervical cancer [73] and pancreatic 
cancer.[74] HOTAIR has been suggested to stimulate the 
degradation of extracellular matrix through the activation 
of matrix metalloproteinases.[70]
SRA-like non-coding RNA (SLNCR1) was 
identified as a mediator of melanoma invasion.[75] 
SLNCR1 interacts with both the androgen receptor (AR) 
and the brain-specific homeobox protein 3A (BRN3A) and 
increases melanoma invasion by upregulating MMP9.[75] 
SLNCR1 is also upregulated in NSCLC.[76] The lncRNA 
growth arrest specific transcript 5 (GAS5) also alters the 
melanoma cell invasion through interaction with matrix 
metalloproteinases. GAS5 is presumed to have tumor 
suppressive potential and is downregulated in multiple 
malignancies.[77-80] Moreover, reduced GAS5 transcript 
levels in tumor tissue are associated with lymph node 
metastasis in cervical cancer [81] and hepatocellular 
cancer.[82] Chen et al.[80] detected the expression of 
GAS5 among five human melanoma cell lines. Reduced 
expression of GAS5 was observed in the SK-MEL-110 
melanoma cell line using RT-PCR compared to the other 
cell lines (HaCaT, A375, SK-MEL-28 and M21). A375 
cells expressed the highest GAS5 level. 
LncRNAs with unknown molecular mechanism
Small nucleolar RNA host gene 5 (SNHG5) is 
classified as a non-protein-coding multiple small nucleolar 
RNA host. The mechanism by which SNHG5 might 
interfere with the pathogenesis of malignant melanoma is 
not known yet. SNHG5 was also studied in gastric cancer, 
where SNHG5 was downregulated and associated with 
tumor, node and metastasis stage.[83]
Analysis of altered intergenic domains in metastatic 
melanoma by Lessard et al.[84] uncovered the cancer 
susceptibility candidate 15 (CASC15) as a lncRNA 
associated with metastatic cutaneous melanoma. The 
molecular interactions of CASC15 in melanoma is still 
unknown. In contrast to the oncogenic properties of 
CASC15 in melanoma, in neuroblastoma, another neural 
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crest derived tumor, CASC15 has been described as a 
tumor suppressor lncRNA.[85] This points at context 
specific functions of lncRNAs, as documented previously 
for microRNAs.[86] 
LNCRNAS AS BIOMARKERS FOR 
CUTANEOUS MELANOMA
Traditionally, diagnosis of malignancies is based on 
tissue samples containing tumor cells. Expression levels 
of specific lncRNAs in tissue may become an additional 
tool in the pathologists’ armamentarium for difficult to 
diagnose cases.[87] Furthermore, sensitive molecular 
detection methods enable the identification of tumor-
derived nucleic acids in serum or plasma. Such liquid 
biopsies can also be interrogated for lncRNAs. LncRNAs 
with overexpression levels reflected in serum or plasma, 
are therefore easily accessible candidate biomarkers for 
early tumor detection or disease progression.
All but one (GAS5) of 13 lncRNAs reviewed are 
upregulated in melanoma compared with normal tissue, 
and three lncRNAs are suggested to be melanoma 
specific (RMEL3, SAMMSON, LLME23). GAS5 
is downregulated in melanoma and in multiple other 
malignancies.[77-80]
The expression levels of ANRIL [52, 88, 89] and 
SNHG5 [90] in primary melanoma samples have so far 
been compared with normal tissue only and have not 
yet been studied in relation to melanoma stage. ANRIL 
was overexpressed in 18 cutaneous and 10 uveal primary 
melanoma samples compared with 9 healthy tissue 
samples including benign nevi, choroid and retina tissue.
[88]
The serum SNHG5 levels were significantly higher 
in 24 patients with melanoma compared to 15 healthy 
subjects and 5 patients with squamous cell carcinoma 
(SCC). In five patients with melanoma, the serum levels 
of SNHG5 were assessed before and after surgery. A 
significant decrease of the SNHG5 serum levels was 
observed after surgery, and in two of the five patients 
the serum levels increased at the time of recurrence. The 
expression of SNHG5 was also assessed in tissue samples 
of 36 primary melanoma and in four nevi. No significant 
differences in the SNHG5 level between both tissue types 
was observed.[90]
Below we group the findings of relevance for 
biomarker development into prognostic markers based on 
serum or plasma samples, prognostic markers based on 
tissue samples, and markers for lymph node involvement. 
In case lncRNAs have been investigated for their clinical 
relevance in melanoma tissue as well as in blood samples, 
we present the findings under serum or plasma markers. 
Prognostic markers in serum or plasma
The prognostic value of SPRY4-IT1 [91] and 
HOTAIR [72] was demonstrated in plasma and serum. 
Plasma levels of SPRY4-IT1 were increased in 70 
melanoma patients compared with 79 healthy controls.
[91] In addition, multivariate survival analysis revealed 
that a high SPRY4-IT1 expression level in plasma is an 
independent negative prognostic factor for overall survival 
in melanoma patients. Cantile et al.[72] recently reported 
a progressive increase in expression levels of HOTAIR in 
tumor tissue as well as in serum from pT1 stage to pT4 
stage. Tang et al.[70] reported that HOTAIR is significantly 
overexpressed in metastatic lymph nodes compared with 
matched primary melanomas. Data mining of publicly 
available gene expression data revealed a higher HOTAIR 
expression level in melanomas compared with non-tumor 
tissues. This is in contrast with the findings of Tian et 
al.[62] who found similar HOTAIR expression levels in 
63 melanoma samples and paired adjacent normal tissue. 
Prognostic markers in melanoma tissue
BANCR[45] and SLNCR1 [75] expression levels in 
primary melanoma samples were associated with lower 
survival rates. Li et al.[45] showed that the expression of 
BANCR was higher in 103 samples of primary melanoma 
compared to 12 melanocytic nevus samples. Furthermore, 
BANCR expression increased with clinical stages of 
malignant melanoma. An analysis of 72 patients revealed 
that the overall survival rates of patients with a high 
expression of BANCR in the primary tumor was lower 
than that of patients with a low expression of BANCR. 
[45] The clinical relevance of SLNCR1 was analyzed 
based on TCGA data. SLNCR1 expression was assessed 
across 150 randomly selected human melanoma tumors 
and high expression of SLNCR1 appeared to be associated 
with shorter overall survival.[75]
CASC15 is a marker of relapse in stage III 
melanoma patients.[84] The correlation of CASC15 
expression level with shorter survival was based on 
RNA in situ hybridization in 141 formalin-fixed paraffin-
embedded lymph node metastasis specimens. 
LncRNA as a marker of lymph node metastasis
MALAT1 [62] and UCA1 [63] are upregulated in 
melanoma and both may indicate lymph node metastasis 
in melanoma. The expression of MALAT1 in 63 lymph 
node metastatic tissue samples was higher than in paired 
primary melanomas. In addition, patients with lymph node 
metastasis exhibited a higher expression of UCA1 in the 
primary tumor than those without lymph node metastasis.
[62] However, no significant difference in MALAT1 nor 
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UCA1 expression was detected in (only) three pairs of 
primary melanoma and matched lymph node metastatic 
tissues by Tang et al.[70]
LNCRNAS AS THERAPEUTIC TARGETS 
IN CUTANEOUS MELANOMA
From the 13 lncRNAs that are reviewed here, one 
has an unknown function in oncogenesis (SNHG5), 
one is regarded as a tumor-suppressor (GAS5) and 11 
have pro-oncogenic properties in melanoma. Selective 
knockdown of these targets is a promising therapeutic 
strategy, especially if the expression is tumor specific as 
this would avoid unwanted effects in normal tissues. Most 
lncRNAs have been studied through RNA-interference 
mediated knock-down, two were also studies through 
ectopic overexpression. Of note, the latter will only reveal 
functions in trans, as the cis-regulatory lncRNA function 
requires expression from the endogenous locus in the 
genome.
Knockdown of lncRNAs with oncogenic 
properties
RNAi-dependent knockdown of SPRY4-IT1 in 
the melanoma cell lines WM1552C and A375 prevented 
cell growth and resulted in decreased invasion and the 
induction of apoptosis.[40, 41, 77, 91, 92] Knockdown 
of HOTAIR in the human metastatic melanoma cell line 
A375 was shown to inhibit the motility and invasiveness 
of melanoma cells and resulted in a reduced degradation 
of the extracellular matrix.[70] In vitro studies using 
melanoma cell line A375 revealed that MALAT1 
knockdown resulted in reduced cell migration.[62] 
The underlying mechanism by which MALAT1 affects 
melanoma cell migration has not yet been elucidated. 
Knockdown of UCA1 in A375 and SK-MEL-2 cell 
lines decreased the number of invasive melanoma cells 
and increased the fraction of G0/G1 phase cells.[63] In 
addition, in vitro studies by Tian et al.[62] revealed that 
A375 cells with reduced expression of UCA1 lncRNA, 
migrated less effectively through a transwell assay. 
Therefore, overexpression of UCA1 in A375 melanoma 
cells could promote cell migration.[62] Knockdown of 
CASC15 revealed that CASC15 regulates melanoma cell 
phenotype switching between proliferative and invasive 
states.[84] CASC15 knockdown in melanoma cell 
lines was associated with downregulation of the master 
regulator transcription factors MITF and SOX10 and 
concomitant upregulation of invasive signature genes.[84] 
ANRIL knockdown in the A375 cells led to an increase of 
the tumor suppressor proteins CDKN2A and CDKN2B; 
a decrease of the metastatic ability of melanoma cells 
in both a transwell and a wound-healing assay; and a 
reduction of clonogenicity in a colony formation assay.
[88] Knockdown of the most prevalent isoform of 
SLNCR1 in the melanoma short-term culture WM1976 
decreased melanoma invasion without affecting cell 
motility and proliferation.
SAMMSON, RMEL3 and LLME23 are pro-
oncogenic and are exclusively upregulated in melanoma 
cells.[50, 51, 58, 60] SAMMSON functions as a lineage 
survival oncogene. Lineage survival oncogenes are 
characterized by a high lineage-specific expression, are 
upregulated in tumor cells derived from that lineage, and 
are required for their survival. ASO- and RNAi-mediated 
knockdown of SAMMSON reduced clonogenicity of all 
SAMMSON-expressing melanoma cultures and induced 
apoptosis of the melanoma cells, irrespective of BRAF, 
NRAS or TP53 status. 
In vivo, the intravenous administration of a 
SAMMSON-specific antisense oligonucleotide in a 
melanoma patient derived tumor xenograft (PDTX) 
significantly reduced tumor growth. The combined 
administration of a SAMMSON-specific ASO and 
dabrafenib, a BRAF inhibitor, induced apoptosis in the 
PDTX model, whereas administration of dabrafenib alone 
only inhibited tumor growth. In addition, the combination 
of BRAF inhibitors and SAMMSON-targeting ASOs 
did not show signs of toxicity in contrast to combination 
treatment with BRAF and MEK inhibitors.[58] 
RMEL3 knockdown in BRAFV600E melanoma cells 
of the A375-SM cell line reduced colony formation and 
caused an accumulation of cells in the G1 phase together 
with an increase in apoptosis. A reverse phase protein 
array analysis was carried out to assess the effect of 
RMEL3 knockdown in A375-SM cells. A decrease in 
protein levels of AKT1 (pAKT), BRAF, RB1 (pRB) and 
CCNB1 (cyclin B1) together with an increase in PTEN 
and the G1/S cyclin-dependent kinase inhibitors CDKN1A 
and CDKN1B was observed, which reflects an inactivation 
of the critical MAPK and PI3K signaling pathways.[51] 
Overexpression of LLME23 in YUSAC melanoma 
cells was induced through transfection with a LLME23-
encoding plasmid and resulted in the upregulation of 
RAB23. In contrast, knockdown of LLME23 lead to 
a decreased expression of RAB23. LLME23-depleted 
YUSAC cells showed a significant decrease in their 
colony forming ability in soft-agar and the same cells 
demonstrated a 75% smaller tumor volume 38 days 
after injection into nude mice. LLME23 appears to be 
exclusively expressed in human melanoma cell lines. The 
latter feature might indicate an association of LLME23 
expression with the etiology of human melanoma, 
however future research in patient samples should confirm 
this statement.[60] 
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Overexpression of lncRNAs with a tumor 
suppressor function
GAS5 is the only reported lncRNA acting as 
tumor suppressor in melanoma. Overexpression of 
GAS5 in the SK-MEL-110 melanoma cell line reduced 
the migration and invasiveness and lead to a decrease in 
MMP2 expression, a protein specifically involved in type 
IV collagen degradation. Knockdown of GAS5 in A375 
cell line facilitated wound healing in a wound healing 
assay and increased the proteolytic potential.[80] GAS5 
administered to nude mice significantly inhibited tumor 
growth of GAS5 expressing melanoma cells.[80, 93-95] 
Further research is awaited to explore if enhancing GAS5 
in melanoma cells could have therapeutic value. 
CONCLUDING REMARKS AND FUTURE 
DIRECTIONS
We reviewed lncRNA biology with particular 
attention for discoveries of relevance in the management 
of melanoma. LncRNA research evolves quickly. The 
current state of knowledge indicates that 13 lncRNA genes 
are involved in the pathogenesis of melanoma. Their cell 
or tumor type specific expression pattern makes them good 
candidate diagnostic markers or therapeutic targets.
Besides the need for novel, more effective and less 
toxic therapeutic strategies, there is a need for markers to 
predict or monitor the response to the new and expensive 
metastatic melanoma treatments. Further studies are 
needed to explore the role of lncRNAs for this purpose.
A limitation of the available evidence is that for 
some lncRNAs the reported results are conflicting. For 
example, Tian et al.[62] did not find a significant difference 
between the HOTAIR expression in primary melanoma 
samples and adjacent normal, while a higher HOTAIR 
expression level was detected in melanomas compared 
with nontumor tissues through data-mining of publicly 
available gene expression data.[70] Additional limitations 
may be related to the experimental methods and study 
design. Often the number of samples is relatively low to 
draw reliable conclusions or the selected cell lines are 
only representative for a subset of melanomas observed 
in patients. Results based on underpowered experiments 
need independent confirmation in sufficiently powered 
experiments before science can move forward. 
In conclusion, the case of melanoma illustrates the 
rapidly growing understanding of the role of lncRNAs in 
oncology. In the short term, and after sufficient clinical 
validation, the use of one or multiple lncRNAs for 
melanoma biomarker applications can reasonably be 
expected. This strategy has already been implemented in 
prostate cancer with the introduction of lncRNA PCA3 
as a commercial urine-based diagnostic test.[96] Even 
more important might be the therapeutic offspring of this 
research. Following the example of the miRNAs, blocking 
lncRNAs may also have therapeutic potential. The high 
tumor specificity of some of the lncRNAs might be a key 
success factor in this endeavor.
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